BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33894019)

  • 1. Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.
    Yang X; Sun D; Xiang H; Wang S; Huang Y; Li L; Cheng X; Liu H; Hu F; Cheng Y; Ma T; Hu M; Tian H; Tian S; Zhou Y; Zhang P; Zhang XJ; Ji YX; Hu Y; Li H; She ZG
    Hepatology; 2021 Sep; 74(3):1319-1338. PubMed ID: 33894019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
    Hu Y; He W; Huang Y; Xiang H; Guo J; Che Y; Cheng X; Hu F; Hu M; Ma T; Yu J; Tian H; Tian S; Ji YX; Zhang P; She ZG; Zhang XJ; Huang Z; Yang J; Li H
    Hepatology; 2021 Nov; 74(5):2508-2525. PubMed ID: 34231239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1.
    Yang Q; Chen X; Zhang Y; Hu S; Hu F; Huang Y; Ma T; Hu H; Tian H; Tian S; Ji YX; She ZG; Zhang P; Zhang XJ; Hu Y; Yang H; Yuan Y; Li H
    Hepatology; 2021 Dec; 74(6):3018-3036. PubMed ID: 34272738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease.
    Du J; Ji X; Xu B; Du Q; Li Y; Zhou B; Liu X; Xu Z; Jiang Y; Kou B; Li Z; Cui C; Lin J
    Metabolism; 2024 Mar; 152():155769. PubMed ID: 38158076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
    Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice.
    Li K; Zhang K; Wang H; Wu Y; Chen N; Chen J; Qiu C; Cai P; Li M; Liang X; Su D
    Metabolism; 2021 Jan; 114():154349. PubMed ID: 32888949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the Hypoxia Inducible Factor 1α Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones.
    Asai Y; Yamada T; Tsukita S; Takahashi K; Maekawa M; Honma M; Ikeda M; Murakami K; Munakata Y; Shirai Y; Kodama S; Sugisawa T; Chiba Y; Kondo Y; Kaneko K; Uno K; Sawada S; Imai J; Nakamura Y; Yamaguchi H; Tanaka K; Sasano H; Mano N; Ueno Y; Shimosegawa T; Katagiri H
    Gastroenterology; 2017 May; 152(6):1521-1535.e8. PubMed ID: 28088462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis.
    DeBosch BJ; Chen Z; Saben JL; Finck BN; Moley KH
    J Biol Chem; 2014 Apr; 289(16):10989-10998. PubMed ID: 24519932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte caveolin-1 modulates metabolic gene profiles and functions in non-alcoholic fatty liver disease.
    Han M; Piorońska W; Wang S; Nwosu ZC; Sticht C; Wang S; Gao Y; Ebert MP; Dooley S; Meyer C
    Cell Death Dis; 2020 Feb; 11(2):104. PubMed ID: 32029710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smurf1 aggravates non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3 activity-independent manner.
    Zhang X; Zhan Y; Lin W; Zhao F; Guo C; Chen Y; Du M; Li D; Zhang L; An W; Wang HR; Xie P
    FASEB J; 2020 Jun; 34(6):7631-7643. PubMed ID: 32301540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic E4BP4 induction promotes lipid accumulation by suppressing AMPK signaling in response to chemical or diet-induced ER stress.
    Yang M; Zhang D; Zhao Z; Sit J; Saint-Sume M; Shabandri O; Zhang K; Yin L; Tong X
    FASEB J; 2020 Oct; 34(10):13533-13547. PubMed ID: 32780887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG; An XS
    Biochem Biophys Res Commun; 2018 Apr; 498(3):416-423. PubMed ID: 29454967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
    Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
    Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
    Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
    J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 19. TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4α stability.
    Xiao MC; Jiang N; Chen LL; Liu F; Liu SQ; Ding CH; Wu SH; Wang KQ; Luo YY; Peng Y; Yan FZ; Zhang X; Qian H; Xie WF
    J Hepatol; 2024 May; 80(5):778-791. PubMed ID: 38237865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
    Zhang M; Tang Y; Tang E; Lu W
    Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.